Last updated: February 13, 2026
What Is the Market Status and Price Projection for NDC 00781-7080?
NDC 00781-7080 corresponds to Venclexta (Venetoclax), a BCL-2 inhibitor approved for treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), acute myeloid leukemia (AML), and for other hematologic malignancies. Its market landscape reflects evolving indications, competitive dynamics, and pricing strategies.
Market Overview
Product Indications and Approved Uses
Venclexta is approved by the FDA for multiple hematological cancers, including:
- Chronic lymphocytic leukemia (CLL) with or without 17p deletion
- Small lymphocytic lymphoma (SLL)
- Acute myeloid leukemia (AML) in combination with hypomethylating agents for newly diagnosed patients aged ≥75 or with comorbidities
- Other off-label and research uses under investigation
Market Size and Growth Drivers
- Total U.S. sales (2022): Estimated at approximately $3.2 billion (IQVIA).
- Market growth rate: Projected compound annual growth rate (CAGR) of 8-10% through 2025, driven by expanding indications, combination therapies, and increased diagnosis rates.
Competitive Landscape
Venclexta competes with other BCL-2 inhibitors and targeted therapies such as:
- AbbVie/Roche's Venclexta (primary)
- Gilead's magrolimab (in emerging pipeline)
- Other targeted agents: Ibrutinib, acalabrutinib, and idelalisib
Patent exclusivity extends until 2030, with some patent protections expiring earlier for specific formulations, impacting market penetration.
Pricing and Reimbursement
Price Points
- Wholesale acquisition cost (WAC): Approximate list price of Venclexta is $10,950 per 28-day supply (comparable across formulations).
- Average selling price (ASP): Slightly lower, adjusted for discounts and rebates.
Patient Cost and Insurance Coverage
- The drug's high list price often results in significant out-of-pocket expenses for uninsurance or underinsured patients.
- Insurance reimbursement varies; most commercial payers and government programs provide coverage with prior authorization.
Pricing Trends
- Price remains relatively stable but has faced scrutiny and pressure from payers aiming for cost containment.
- Trial data suggests increasing use in combination regimens may raise overall therapy costs, though unit drug costs remain stable.
Price Projections (2023-2025)
| Year |
Estimated Average Price (per 28-day supply) |
Main Influences |
| 2023 |
$10,950 |
Stable, with inflation adjustments |
| 2024 |
$11,050–$11,200 |
Slight inflation, expanded indications |
| 2025 |
$11,200–$11,300 |
Market stabilization, patent protections |
Factors Affecting Price Trajectory
- Patent Cliff Risks: Expiry of manufacturing patents could lead to biosimilar entries post-2028, pressuring prices downward.
- Regulatory and Policy Changes: Increased focus on drug pricing transparency and negotiations could influence pricing strategies.
- Market Penetration: Higher adoption in combination therapies and expanded indications could sustain or increase overall revenues without significantly changing unit prices.
Regulatory and Patent Outlook
- Patent protections are expected through 2030, with some generics or biosimilars possibly entering as early as 2028.
- Title X exclusivity is maintained through data protections and patents, restricting generic entry until expiration.
Key Market Considerations
- Volumes are driven by adoption in frontline and relapsed settings.
- Cost-effectiveness analyses influence formulary decisions and reimbursement.
- Competitive therapies with similar efficacy profiles may constrain pricing power in the medium term.
Summary
Venclexta (NDC 00781-7080) remains a high-revenue hematology-oncology drug with a stable pricing outlook through 2025, contingent on patent protections and market expansion. Market growth is driven by increasing indications and combination therapies, though competitive pressures and policy developments could temper future pricing flexibility.
Key Takeaways
- The drug's estimated price per 28-day supply remains around $11,000 through 2025.
- Market growth depends on expanded indications and combination use; competition and patent expiry pose future risks.
- Reimbursement challenges persist due to high costs, influencing access and sales volume.
- Patent protections extend to 2030, with early biosimilar entry possible after 2028.
- Liquid and fixed-dose formulations, along with evolving clinical data, impact pricing and market penetration.
FAQs
1. What factors most influence Venclexta's market share?
Indication approvals, competition with similar agents, patent status, and payer reimbursement policies.
2. How does Venclexta's price compare to similar therapies?
It is generally higher than older therapies like ibrutinib but aligns with targeted therapy prices; around $10,950 per month.
3. Are biosimilars expected to impact Venclexta's price?
Biosimilars could reduce prices post-2030 once patent protections lapse, causing competitive price reductions.
4. How has recent clinical trial data affected pricing projections?
Positive data supporting combination therapy may sustain or increase total treatment costs but has minimal effect on unit pricing.
5. What policy changes could influence future pricing?
Government initiatives around drug pricing transparency, negotiation authority for Medicare, and patent reforms could reshape the pricing landscape.
Sources:
[1] IQVIA. "Pharmacy Data and Sales Market Share Reports." 2022.
[2] FDA. “Venclexta (Venetoclax) Prescribing Information.” 2022.
[3] Evaluate Pharma. "Global Oncology Market Outlook 2022."
[4] U.S. Patent and Trademark Office. Patent expiration timelines.
